Payden & Rygel’s Abbott Laboratories Position
Does Payden & Rygel own Abbott Laboratories (ABT)? Not currently — the last reported position was 164.5K shares worth $18M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$18M
Q4 2023
Shares
164.5K
% of Portfolio
+1.26%
Quarters Held
12
position exited
Position History ABT
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2023 | 164.5K | $18M | +1.26% |
| Q2 2023 | 210.9K | $23M | +1.62% |
| Q1 2023 | 222.3K | $23M | +1.33% |
| Q4 2022 | 112.2K | $12M | +0.66% |
| Q3 2022 | 201.5K | $20M | +1.14% |
| Q2 2022 | 192.6K | $21M | +1.26% |
| Q1 2022 | 192.6K | $23M | +1.15% |
| Q4 2021 | 279.7K | $39M | +1.82% |
| Q3 2021 | 280.6K | $33M | +1.72% |
| Q2 2021 | 280.6K | $33M | +1.55% |
| Q1 2021 | 18.7K | $2M | +0.10% |
| Q4 2020 | 175.4K | $19M | +0.98% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Payden & Rygel’s full portfolio or all institutional holders of ABT.